Remarkable Intracranial Response to Sotorasib in a Patient With KRASG12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report

AbstractSotorasib is a KRASG12C inhibitor that recently received approval for use in locally advanced or metastatic KRASG12C-mutated NSCLC. CodeBreaK100, the phase 2 clinical trial leading to the approval of sotorasib, excluded patients with untreated brain metastases; there have been no reports des...

Full description

Saved in:
Bibliographic Details
Published in:JTO clinical and research reports 2022-12, Vol.3 (12), p.100428-100428, Article 100428
Main Authors: Yeh, Justin, MD, Marks, Jennifer A., MD, Alzeer, Ali H., MD, Sloan, Emily A., MD, PhD, Varghese, Reshma, MD, Paudel, Nitika, MD, PhD, Reuss, Joshua E., MD, Bergquist, Peter J., MD, Liu, Stephen V., MD, Kim, Chul, MD, MPH
Format: Article
Language:English
Subjects:
Brain metastases
Case Report
Hematology, Oncology, and Palliative Medicine
KRAS G12C
Non–small cell lung cancer
Sotorasib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AbstractSotorasib is a KRASG12C inhibitor that recently received approval for use in locally advanced or metastatic KRASG12C-mutated NSCLC. CodeBreaK100, the phase 2 clinical trial leading to the approval of sotorasib, excluded patients with untreated brain metastases; there have been no reports describing efficacy of sotorasib on untreated brain metastases. We present a case of a patient with active untreated brain metastases with resulting disorientation and weakness who has radiographic response and complete resolution of neurologic symptoms with sotorasib. Our case illustrates the intracranial activity of sotorasib, but additional studies are needed to characterize the intracranial response rate and duration of response in these patients.
ISSN:2666-3643
2666-3643
DOI:10.1016/j.jtocrr.2022.100428